Robinhood, Applovin jump as S&P 500 reshuffle boosts index entrants
LONDON - Medical technology company Smith+Nephew (LSE:SN, NYSE:SNN) announced Thursday that Dr. Garheng Kong will join its Board as an independent Non-Executive Director effective September 1, 2025.
According to the company’s press release, Dr. Kong will also serve as a member of the Audit Committee. He is currently the managing partner and co-founder of HealthQuest Capital and serves as lead independent director of Laboratory Corporation of America (LabCorp) and as a non-executive director at several healthcare companies including Xeris Biopharma Holdings Inc, Lunit Inc, and IKS Health.
Dr. Kong previously held positions as managing general partner of Sofinnova Investments, Inc. and has board experience with various medical technology and healthcare companies.
Smith+Nephew Chair Rupert Soames stated that Dr. Kong brings "wide experience in the medtech and biopharma sectors" along with "significant clinical, technical and investment expertise" from his roles as an executive, non-executive director, and investor.
The company noted that no disclosure obligations arise under paragraphs (1) to (6) of UKLR 6.4.8 R of the UK Listing Authority’s Listing Rules regarding the appointment.
Smith+Nephew, founded in Hull, UK in 1856, focuses on the repair, regeneration, and replacement of soft and hard tissue through its three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company reported annual sales of $5.8 billion in 2024 and operates in approximately 100 countries with 17,000 employees.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.